γc cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1.

Autor: Singh R; Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India., Gupta U; Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India., Srivastava P; Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India., Paladhi A; Cellular Immunology Laboratory, Department of Zoology, The University of Burdwan, PurbaBardhhaman, India., Sk UH; Chittaranjan National Cancer Institute, Kolkata, India., Hira SK; Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India; Cellular Immunology Laboratory, Department of Zoology, The University of Burdwan, PurbaBardhhaman, India. Electronic address: sumithira2008@gmail.com., Manna PP; Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, India. Electronic address: pp_manna@yahoo.com.
Jazyk: angličtina
Zdroj: Cytotherapy [Cytotherapy] 2022 Dec; Vol. 24 (12), pp. 1232-1244. Date of Electronic Publication: 2022 Aug 31.
DOI: 10.1016/j.jcyt.2022.07.012
Abstrakt: Background Aims: The stimulatory natural killer-dendritic cell axis in the tumor microenvironment could play a critical role in stimulating cytotoxic T cells and driving immune responses against cancer.
Methods: We established a novel treatment protocol by adroitly combining chemotherapy with doxorubicin and immunotherapy with dendritic cells and natural killer cells against a highly aggressive and malignant lymphoma called Dalton's lymphoma.
Results: Our data suggest that binary application of adoptive cell therapy and chemotherapy nearly cures (95%) early-stage experimental lymphoma. In the case of mid-stage cancer, the success rate was significantly lower but still impressive (75%). Our results demonstrated that the application of combination therapy in early-stage cancer significantly reduced the tumor volume and extended the lifespan of the experimental animal in addition to reinvigorating the immune system, including restoring the effector functions of dendritic cells and natural killer cells. The novel protocol limits the metastasis of tumor cells in vascularized organs and rearms the adaptive immune response mediated by dendritic cells and CD4 + and CD8 + T cells.
Conclusions: Combination therapy in the early stage alters the cytokine profile, increases interferon-γ and tumor necrosis factor-α in the serum of treated animals and downregulates programmed cell death protein 1 expression in CD8 + T cells. Thus, cooperative and cognitive interactions between dendritic cells and natural killer cells in addition to therapy with doxorubicin promote the immune response and tumoricidal activities against lymphoma.
Competing Interests: Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article.
(Copyright © 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: